MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202611065908 A) filed by Mrs. Preeti Semwal; Ms. Arti Ashokrao Ingole; Dr. Hitanshi Darji; Ms. Ashwini Bhausaheb Pansare; Ms. Aishwarya Sunil Pandit; Ms. Tavleen Kaur; Ms. Priya Shriram Vaware; Dr. Khushboo Saxena; Dr. Nisha Devi; Mr. Himangshu Jyoti Sharma; Ms. Samima Nasrin Rahman; and Ms. Taljinder Kaur on May 25, 2026, for Brain Targeted Nanoparticle Delivery System For Parkinson’s Di Sease.
Inventors include Mrs. Preeti Semwal; Ms. Arti Ashokrao Ingole; Dr. Hitanshi Darji; Ms. Ashwini Bhausaheb Pansare; Ms. Aishwarya Sunil Pandit; Ms. Tavleen Kaur; Ms. Priya Shriram Vaware; Dr. Khushboo Saxena; Dr. Nisha Devi; Mr. Himangshu Jyoti Sharma; Ms. Samima Nasrin Rahman; and Ms. Taljinder Kaur.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: The present invention discloses a brain-targeted nanoparticle delivery system for improving therapeutic drug delivery across the blood-brain barrier for the management of Parkinsdoisn’eas se. Biodegradable polymeric nanoparticles are formulated from poly(lactic-co-glycolic acid), polyethylene glycol, and chitosan, and surface-functionalized with targeting ligands such as transferrin or lactoferrin for receptor-mediated transcytosis. The optimized targeted nanoparticles exhibit a particle size of 138 ± 10 nm, polydispersity index of 0.19 ± 0.02, drug entrapment efficiency of 89 ± 3 percent, and drug loading of 10.5 ± 0.8 percent. In vitro studies demonstrate sustained drug release of 88 ± 2 percent at 48 hours, blood-brain barrier transport efficiency of 68 ± 4 percent, and enhanced cellular uptake with fluorescence intensity of 620 ± 25 AU. The formulation retains 92 percent stability after three months at 4°C. The invention provides a stable, efficient, and targeted nanoparticulate platform for improved Parkinson’s disease therapy with reduced systemic adverse effects.
Disclaimer: Curated by HT Syndication.
